- Home
- CANF vs BMRA Comparison
CANF vs BMRA Comparison
Compare CANF & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- BMRA
- Stock Information
- Founded
- CANF 1994
- BMRA 1971
- Country
- CANF Israel
- BMRA United States
- Employees
- CANF N/A
- BMRA N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CANF Health Care
- BMRA Health Care
- Exchange
- CANF Nasdaq
- BMRA Nasdaq
- Market Cap
- CANF 9.6M
- BMRA 7.9M
- IPO Year
- CANF N/A
- BMRA N/A
- Fundamental
- Price
- CANF $0.59
- BMRA $2.85
- Analyst Decision
- CANF Strong Buy
- BMRA
- Analyst Count
- CANF 2
- BMRA 0
- Target Price
- CANF $14.50
- BMRA N/A
- AVG Volume (30 Days)
- CANF 174.9K
- BMRA 32.9K
- Earning Date
- CANF 11-27-2025
- BMRA 10-10-2025
- Dividend Yield
- CANF N/A
- BMRA N/A
- EPS Growth
- CANF N/A
- BMRA N/A
- EPS
- CANF N/A
- BMRA N/A
- Revenue
- CANF $560,000.00
- BMRA $5,311,000.00
- Revenue This Year
- CANF $461.72
- BMRA N/A
- Revenue Next Year
- CANF N/A
- BMRA N/A
- P/E Ratio
- CANF N/A
- BMRA N/A
- Revenue Growth
- CANF N/A
- BMRA N/A
- 52 Week Low
- CANF $0.59
- BMRA $2.08
- 52 Week High
- CANF $3.12
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- CANF 32.24
- BMRA 45.61
- Support Level
- CANF $0.60
- BMRA $2.68
- Resistance Level
- CANF $0.64
- BMRA $2.83
- Average True Range (ATR)
- CANF 0.03
- BMRA 0.11
- MACD
- CANF 0.00
- BMRA 0.01
- Stochastic Oscillator
- CANF 2.03
- BMRA 54.84
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.